SEND
loading
Sending mail...

Thanks!

Your message has been
successfully submitted.

Hemophilia Awareness

View
History
ZoomRx Outlook
1800s
The Royal Disease
1900
1950s
The First Treatment
1950
1965
Cryoprecipitate Discovery
1965
1970s
Home Therapy
1970
1973
Hemophilia Care Act
1973
1980s
Bad Blood
Scare
1980
1992
Recombinant Therapy
1992
2000s
Marching Towards Cure
2000

Long Acting Therapies Will Revolutionize Hemophilia Treatment

A ZoomRx pilot study with 35 Hematologists.
Treating physicians anxiously await long acting therapies (LAT).
Awareness
Perception
Penetration
Patient Share
Current Unmet Needs
Current Therapies Are Inconvenient

9/10 MDs
have convenience issues

"Effective but difficult to administer, induce inhibitors, short half life."
"Convenience needs to be improved. Current treatment requires frequent administration."
"Current therapies requires multiple administration, half life is too short & inconvenient."
Therapy Ratings
LAT Will Greatly Improve Convenience Without Sacrificing Efficacy & Safety
"By decreasing the frequency. It will improve compliance."
"It would be a major breakthrough & will take market share."
Potential Barriers
Cost & Insurance Coverage May Slow LAT Rapid Adoption

7/10 MDs
are concerned about cost / insurance issues

"Insurance approval, possibility of anaphylaxis or increase in rate of allergic reactions."
"Cost would be the biggest barrier and insurance companies may not provide payments for these newer agents."
"Drugs will likely be priced prohibitively expensive and require an extensive authorization process."
Facebook/Twitter/LinkedIn Share

Request a FREE Print Version*

Enter your info below.


*Limited print copies available

Share it on the web